Current Treatment Options in Oncology

, Volume 13, Issue 1, pp 24–34 | Cite as

Neuroendocrine Pancreatic Tumors: Guidelines for Management and Update

Endocrine Tumors (O Clark and A Dackiw, Section Editors)

Opinion statement

Pancreatic neuroendocrine tumors (PanNETs) are a diverse group of rare neoplasms. Commonly referred to as islet cell tumors, PanNETs are classified as functional or nonfunctional depending on their production of specific pancreatic endocrine hormones (e.g. insulin, gastrin, glucagon, and others) and association with the resultant clinical syndromes. While most PanNETs are sporadic, syndromic patients, in particular those with multiple endocrine neoplasia type 1 (MEN-1) and von Hippel Lindau (VHL), are at increased risk of developing these tumors. Recent investigations of patients with sporadic and syndromic PanNETs have elucidated critical pathways in tumor development, such as mammalian target of rapamycin (mTOR) signaling and its downstream growth factors such as vascular endothelial growth factor (VEGF). Prognosis ranges from favorable for localized, low-grade neoplasms to poor for advanced, high-grade tumors. Regardless of the stage at presentation, surgery is the first-line therapy for patients with disease amenable to surgical resection. We favor formal pancreatectomy with conventional lymph node sampling for the vast majority of patients, either through open or laparoscopic techniques. Those with insulinomas, however, may be candidates for enucleation. Cytoreductive surgery is also recommended for patients with locoregional recurrences or hepatic metastases. Regional adjuvants such as radiofrequency ablation (RFA), transarterial chemoembolization (TACE), and others are often employed in an attempt to palliate symptoms and prolong survival. Unfortunately, cytotoxic chemotherapy has been largely ineffective in treating patients with PanNETs. The somatostatin analogue octreotide, however, has been effective in palliating symptoms and slowing the progression of disease. Other promising systemic agents, including sunitinib and everolimus, have targeted critical PanNET signaling pathways. In summary, surgery remains the principal therapeutic strategy for patients with PanNETs, but continued research may identify more robust systemic therapies for those with advanced disease.

Keywords

Neuroendocrine pancreatic tumors Neoplasms Islet cell tumors Pancreatic endocrine hormones PanNETs Multiple endocrine neoplasia type 1 (MEN-1) von Hippel Lindau (VHL) Pancreatectomy 

Notes

Disclosure

No potential conflicts of interest relevant to this article were reported.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–72.PubMedCrossRefGoogle Scholar
  2. 2.
    Carriaga MT, Henson DE. Liver, gallbladder, extrahepatic bile ducts, and pancreas. Cancer. 1995;75:171–90.PubMedCrossRefGoogle Scholar
  3. 3.
    Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol. 2008;19:1727–33.PubMedCrossRefGoogle Scholar
  4. 4.
    Grimelius L, Hultquist GT, Stenkvist B. Cytological differentiation of asymptomatic pancreatic islet cell tumours in autopsy material. Virchows Arch A Pathol Anat Histol. 1975;365:275–88.PubMedCrossRefGoogle Scholar
  5. 5.
    Kimura W, Kuroda A, Morioka Y. Clinical pathology of endocrine tumors of the pancreas. Analysis of autopsy cases. Dig Dis Sci. 1991;36:933–42.PubMedCrossRefGoogle Scholar
  6. 6.
    Pearse AG. The APUD concept and hormone production. Clin Endocrinol Metab. 1980;9:211–22.PubMedCrossRefGoogle Scholar
  7. 7.
    Wilson BS, Lloyd RV. Detection of chromogranin in neuroendocrine cells with a monoclonal antibody. Am J Pathol. 1984;115:458–68.PubMedGoogle Scholar
  8. 8.
    Wiedenmann B, Franke WW, Kuhn C, et al. Synaptophysin: a marker protein for neuroendocrine cells and neoplasms. Proc Natl Acad Sci U S A. 1986;83:3500–4.PubMedCrossRefGoogle Scholar
  9. 9.
    Tapia FJ, Polak JM, Barbosa AJ, et al. Neuron-specific enolase is produced by neuroendocrine tumours. Lancet. 1981;317:808–11.CrossRefGoogle Scholar
  10. 10.
    Vortmeyer AO, Huang S, Lubensky I, Zhuang Z. Non-islet origin of pancreatic islet cell tumors. J Clin Endocrinol Metab. 2004;89:1934–8.PubMedCrossRefGoogle Scholar
  11. 11.•
    Jiao Y, Shi C, Edil BH, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 2011;331:1199–203.PubMedCrossRefGoogle Scholar
  12. 12.
    Alexakis N, Connor S, Ghaneh P, et al. Hereditary pancreatic endocrine tumours. Pancreatology. 2004;4:417–33.PubMedCrossRefGoogle Scholar
  13. 13.
    Hochwald SN, Zee S, Conlon KC, et al. Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol. 2002;20:2633–42.PubMedCrossRefGoogle Scholar
  14. 14.
    Heitz PU, Komminoth P, Perren A, et al. Pancreatic endocrine tumours. In: DeLellis R, Lloyd R, Heitz PU, et al., editors. World Health Organization classification of tumors pathology and genetics of tumors of endocrine organs. Lyon: IARC; 2004. p. 177–82.Google Scholar
  15. 15.
    Rindi G, Klöppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006;449:395–401.PubMedCrossRefGoogle Scholar
  16. 16.
    Edge SB. Exocrine and endocrine pancreas. In: Edge SB, editor. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.Google Scholar
  17. 17.•
    Kulke MH, Siu LL, Tepper JE, et al. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol. 2011;29:934–43.PubMedCrossRefGoogle Scholar
  18. 18.
    Gibril F, Jensen RT. Diagnostic uses of radiolabelled somatostatin receptor analogues in gastroenteropancreatic endocrine tumours. Dig Liver Dis. 2004;36 Suppl 1:S106–20.PubMedCrossRefGoogle Scholar
  19. 19.
    Rösch T, Lightdale CJ, Botet JF, et al. Localization of pancreatic endocrine tumors by endoscopic ultrasonography. N Engl J Med. 1992;326:1721–6.PubMedCrossRefGoogle Scholar
  20. 20.•
    Khashab MA, Yong E, Lennon AM, et al. EUS is still superior to multidetector computerized tomography for detection of pancreatic neuroendocrine tumors. Gastrointest Endosc. 2011;73:691–6.PubMedCrossRefGoogle Scholar
  21. 21.
    Doppman JL, Miller DL, Chang R, et al. Insulinomas: localization with selective intraarterial injection of calcium. Radiology. 1991;178:237–41.PubMedGoogle Scholar
  22. 22.
    Guettier JM, Kam A, Chang R, et al. Localization of insulinomas to regions of the pancreas by intraarterial calcium stimulation: the NIH experience. J Clin Endocrinol Metab. 2009;94:1074–80.PubMedCrossRefGoogle Scholar
  23. 23.
    Sosa JA, Bowman HM, Gordon TA, et al. Importance of hospital volume in the overall management of pancreatic cancer. Ann Surg. 1998;228:429–38.PubMedCrossRefGoogle Scholar
  24. 24.
    Waghorn DJ. Overwhelming infection in asplenic patients: current best practice preventive measures are not being followed. J Clin Pathol. 2001;54:214–8.PubMedCrossRefGoogle Scholar
  25. 25.•
    Mayo SC, de Jong MC, Pulitano C, et al. Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol. 2010;17:3129–36.PubMedCrossRefGoogle Scholar
  26. 26.
    Sarmiento JM, Que FG, Grant CS, et al. Concurrent resections of pancreatic islet cell cancers with synchronous hepatic metastases: outcomes of an aggressive approach. Surgery. 2002;132:976–82.PubMedCrossRefGoogle Scholar
  27. 27.•
    De Jong MC, Farnell MB, Sclabas G, et al. Liver-directed therapy for hepatic metastases in patients undergoing pancreaticoduodenectomy: a dual-center analysis. Ann Surg. 2010;252:142–8.PubMedCrossRefGoogle Scholar
  28. 28.
    Steinmüller T, Kianmanesh R, Falconi M, et al. Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2008;87:47–62.PubMedCrossRefGoogle Scholar
  29. 29.
    Lehnert T. Liver transplantation for metastatic neuroendocrine carcinoma: an analysis of 103 patients. Transplantation. 1998;66:1307–12.PubMedCrossRefGoogle Scholar
  30. 30.
    Madoff DC, Gupta S, Ahrar K, et al. Update on the management of neuroendocrine hepatic metastases. J Vasc Interv Radiol. 2006;17:1235–49.PubMedCrossRefGoogle Scholar
  31. 31.
    Gupta S, Johnson MM, Murthy R, et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer. 2005;104:1590–602.PubMedCrossRefGoogle Scholar
  32. 32.
    Akyildiz HY, Mitchell J, Milas M, et al. Laparoscopic radiofrequency thermal ablation of neuroendocrine hepatic metastases: long-term follow-up. Surgery. 2010;148:1288–93.PubMedCrossRefGoogle Scholar
  33. 33.
    Ahmadzadehfar H, Biersack HJ, Ezziddin S. Radioembolization of liver tumors with yttrium-90 microspheres. Semin Nucl Med. 2010;40:105–21.PubMedCrossRefGoogle Scholar
  34. 34.
    Kennedy AS, Dezarn WA, McNeillie P, et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol. 2008;31:271–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Miao N, Pingpank JF, Alexander HR, et al. Percutaneous hepatic perfusion in patients with metastatic liver cancer: anesthetic, hemodynamic, and metabolic considerations. Ann Surg Oncol. 2008;15:815–23.PubMedCrossRefGoogle Scholar
  36. 36.
    Oberg K, Kvols L, Caplin M, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol. 2004;15:966–73.PubMedCrossRefGoogle Scholar
  37. 37.••
    Rinke A, Müller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27:4656–63.PubMedCrossRefGoogle Scholar
  38. 38.
    Moertel CG, Lefkopoulo M, Lipsitz S, et al. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1992;326:519–23.PubMedCrossRefGoogle Scholar
  39. 39.
    Moertel CG, Kvols LK, O’Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer. 1991;68:227–32.PubMedCrossRefGoogle Scholar
  40. 40.
    Kulke MH, Lenz HJ, Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol. 2008;26:3403–10.PubMedCrossRefGoogle Scholar
  41. 41.••
    Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:501–13.PubMedCrossRefGoogle Scholar
  42. 42.
    Yao JC, Phan AT, Chang DZ, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II trial. J Clin Oncol. 2008;26:4311–8.PubMedCrossRefGoogle Scholar
  43. 43.
    Yao JC, Lombard-Bohas C, Baudin E, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol. 2010;28:69–76.PubMedCrossRefGoogle Scholar
  44. 44.••
    Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:514–23..PubMedCrossRefGoogle Scholar
  45. 45.
    Kunz PL, Kuo T, Zahn JM, et al. A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors. J Clin Oncol. 2010;28(15 Suppl):4104.Google Scholar
  46. 46.
    Whipple AO, Frantz VK. Adenoma of islet cells with hyperinsulinism: a review. Ann Surg. 1935;101:1299–335.PubMedCrossRefGoogle Scholar
  47. 47.
    Finlayson E, Clark OH. Surgical treatment of insulinomas. Surgical Clin North Am. 2004;84:775–85.CrossRefGoogle Scholar
  48. 48.
    Fajans SS, Vinik AI. Insulin-producing islet cell tumors. Endocrinol Metab Clin North Am. 1989;18:45–74.PubMedGoogle Scholar
  49. 49.
    Zollinger RM, Ellison EH. Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. Ann Surg. 1955;142:709–23.PubMedCrossRefGoogle Scholar
  50. 50.
    Howard TJ, Stabile BE, Zinner MJ, et al. Anatomic distribution of pancreatic endocrine tumors. Am J Surg. 1990;159:258–64.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Department of SurgeryThe Johns Hopkins HospitalBaltimoreUSA
  2. 2.Department of SurgeryThe Johns Hopkins HospitalBaltimoreUSA

Personalised recommendations